Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) announced that CEO Josh Disbrow will participate in a fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 at 5:00 p.m. ET. The session is moderated by Thomas Flaten, senior research analyst at Lake Street Capital Markets.
The event will be available via webcast at https://lythampartners.com/hc2026/aytu and on the conference home page, with a replay accessible through the same links.
Positive
- None.
Negative
- None.
News Market Reaction – AYTU
In the Jan 14 session, AYTU gained 4.56%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Investor Day announcement | Positive | -3.9% | Announced January 2026 Investor Day focused on EXXUA and KOL discussions. |
| Dec 15 | Product launch news | Positive | +1.3% | Announced U.S. commercial availability of EXXUA for major depressive disorder. |
| Nov 24 | Conference participation | Neutral | +2.5% | Disclosed management presentation at NobleCon21 and webcast availability. |
| Nov 13 | Earnings results | Positive | +0.0% | Reported Q1 fiscal 2026 revenue, net income, cash, and EXXUA patent extension. |
| Nov 05 | Earnings call schedule | Neutral | +1.9% | Announced timing and access details for upcoming Q1 fiscal 2026 results call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and product milestones have not consistently resulted in supportive price reactions, with several upbeat events followed by flat or negative moves.
Over the past few months, AYTU has focused on launching and promoting EXXUA and engaging investors. On November 13, 2025, it reported Q1 fiscal 2026 results with revenue, net income, cash, and a patent extension, but the stock was flat over 24 hours. Subsequent conference and results-announcement notices in early November saw modest gains. EXXUA’s commercial availability on December 15, 2025 coincided with a small positive move, while a later Investor Day announcement on December 18, 2025 saw the stock decline, indicating mixed reactions to otherwise constructive news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.
The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/aytu. A replay will also be available through the same links.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire